Alder BioPharmaceuticals June 15th Short Interest Update

Alder BioPharmaceuticals (NASDAQ:ALDR) has shown a rise of 14.9% or 999,614 shares in the short positions. The bets have increased to 7,711,372 shares on June 15,2016 from 6,711,758 shares on May 31,2016. With respect to the floated shares, the shorts are 19.1%. The days to cover are calculated to be 11, using the standard per day volume of 684,635 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Alder BioPharmaceuticals (NASDAQ:ALDR): The stock opened at $24.68 on Friday but the bulls could not build on the opening and the stock topped out at $25.13 for the day. The stock traded down to $24.30 during the day, due to lack of any buying support eventually closed down at $24.50 with a loss of -5.13% for the day. The stock had closed at $25.83 on the previous day. The total traded volume was 3,292,378 shares.

The company shares have dropped -47.81% from its 1 Year high price. On Jul 1, 2015, the shares registered one year high at $54.90 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $27.67 and the 200 Day Moving Average price is recorded at $26.37.

Alder BioPharmaceuticals (NASDAQ:ALDR) has tumbled 8.85% during the past week and has dropped 15.63% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.34%. Alder BioPharmaceuticals (NASDAQ:ALDR) has underperformed the index by 13.08% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.